Lineage Cell Therapeutics, Inc.
LCTX
AMEX·Healthcare·Biotechnology·Mkt cap $269.2M
$1.08
▼ -1.82%
P/E
-112.50
Mkt Cap
$269.2M
52-Wk Range
$1.00–$2.09
52-Week Range
$1.00 - $2.09
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 12.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-9.2% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LCTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.03 vs -$0.03 consensus (-5.9% surprise). Revenue of $1.1M vs $1.8M expected (-42.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-5.9%
Revenue trend · last 2Q
—
-61%
Q1 26
Q2 26
$1.7M
$1.1M
Margins · last 2Q
Gross
0.0%
Profit
138.6%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: D. Boral Capital · May 4, 2026
vs Industry
How LCTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.